CODE BIOTHERAPEUTICS

code-biotherapeutics-logo

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.
#SimilarOrganizations #People #Financial #Event #Website #More

CODE BIOTHERAPEUTICS

Social Links:

linkedin

Linkedin

x

X

Industry:
Biotechnology Health Care Life Science

Founded:
2020-01-01

Address:
Hatfield, Pennsylvania, United States

Country:
United States

Website Url:
http://www.codebiotx.com

Total Employee:
11+

Status:
Active

Contact:
215-996-3006

Total Funding:
85 M USD


Similar Organizations

atalanta-therapeutics-logo

Atalanta Therapeutics

Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.

axcella-logo

Axcella

Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.

black-diamond-therapeutics-logo

Black Diamond Therapeutics

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule.

enliven-therapeutics-logo

Enliven Therapeutics

Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.

voyager-therapeutics-logo

Voyager Therapeutics

Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.


Current Advisors List

joseph-truitt_image

Joseph Truitt Board Member @ Code Biotherapeutics
Board_member

ed-mathers_image

Ed Mathers Board Member @ Code Biotherapeutics
Board_member
2021-04-01

diana-bernstein_image

Diana Bernstein Board Member @ Code Biotherapeutics
Board_member

not_available_image

Kathy Rouan Board Member @ Code Biotherapeutics
Board_member

rob-lin_image

Rob Lin Board Member @ Code Biotherapeutics
Board_member
2021-04-01

russ-fein_image

Russ Fein Board Member @ Code Biotherapeutics
Board_member

victor-stone_image

Victor Stone Board Member @ Code Biotherapeutics
Board_member
2021-04-01

dmitry-kuzmin_image

Dmitry Kuzmin Board Member @ Code Biotherapeutics
Board_member
2021-04-01

Current Employees Featured

erin-brubaker_image

Erin Brubaker
Erin Brubaker COO @ Code Biotherapeutics
COO
2021-11-01

brian-mcveigh_image

Brian McVeigh
Brian McVeigh Chairman, Chief Executive Officer, and Co-Founder @ Code Biotherapeutics
Chairman, Chief Executive Officer, and Co-Founder

not_available_image

Robert Getts
Robert Getts Chief Technology Officer and Co-Founder @ Code Biotherapeutics
Chief Technology Officer and Co-Founder

not_available_image

Lauren Kaskiel
Lauren Kaskiel Chief Business Officer @ Code Biotherapeutics
Chief Business Officer

not_available_image

Lori Getts
Lori Getts VP Preclinical and Process Development; Co-Founder @ Code Biotherapeutics
VP Preclinical and Process Development; Co-Founder
2021-03-01

Founder


brian-mcveigh_image

Brian McVeigh

not_available_image

Lori Getts

not_available_image

Robert Getts

Investors List

upmc-enterprises_image

UPMC Enterprises

UPMC Enterprises investment in Series A - Code Biotherapeutics

amgen-ventures_image

Amgen Ventures

Amgen Ventures investment in Series A - Code Biotherapeutics

cureduchenne-ventures_image

CureDuchenne Ventures

CureDuchenne Ventures investment in Series A - Code Biotherapeutics

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Series A - Code Biotherapeutics

4bio-capital-partners_image

4BIO Capital

4BIO Capital investment in Series A - Code Biotherapeutics

ucb-ventures_image

UCB Ventures

UCB Ventures investment in Series A - Code Biotherapeutics

takeda-ventures_image

Takeda Ventures

Takeda Ventures investment in Series A - Code Biotherapeutics

jdrf-t1d-fund_image

JDRF T1D Fund

JDRF T1D Fund investment in Series A - Code Biotherapeutics

northpond-ventures_image

Northpond Ventures

Northpond Ventures investment in Series A - Code Biotherapeutics

hatteras-venture-partners_image

Hatteras Venture Partners

Hatteras Venture Partners investment in Series A - Code Biotherapeutics

Key Employee Changes

Date New article
2021-12-02 Code Biotherapeutics Appoints Erin Brubaker as Chief Operating Officer

Official Site Inspections

http://www.codebiotx.com Semrush global rank: 7.76 M Semrush visits lastest month: 437

  • Host name: 147.62.236.23.bc.googleusercontent.com
  • IP address: 23.236.62.147
  • Location: Mountain View United States
  • Latitude: 37.4043
  • Longitude: -122.0748
  • Metro Code: 807
  • Timezone: America/Los_Angeles
  • Postal: 94043

Loading ...

More informations about "Code Biotherapeutics"

Code Biotherapeutics - Crunchbase Company Profile & Funding

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases.See details»

Leadership | Code Biotherapeutics | United States

At SwanBio, Latha led the organization’s lead candidate from the earliest preclinical stage through IND. Previously, Latha served as a Director of Translational Sciences at the Center for Advanced Retinal & Ocular …See details»

Code Bio Company Profile 2024: Valuation, Funding

Code Bio General Information Description. Developer of a non-viral gene therapy designed to treat serious and life-threatening genetic diseases. The company's therapy is leveraging a novel proprietary multivalent synthetic DNA delivery …See details»

Code Biotherapeutics - LinkedIn

Code Biotherapeutics | 3,892 followers on LinkedIn. Pioneering targeted delivery of precision genetic medicines | Code Bio was founded on the belief that more can be done for people living with ...See details»

Code Biotherapeutics, Inc. - BIO International Convention | BIO

Jun 6, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ...See details»

News and Press - JDRF T1D Fund

Jun 7, 2022 For more information, visit www.codebiotx.com. About Northpond Ventures. Northpond Ventures is a multi-billion-dollar science-driven venture capital firm based in …See details»

Code Biotherapeutics (USA) Funding: $85M

Nov 20, 2024 Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene...See details»

Code Biotherapeutics Appoints Erin Brubaker as Chief Operating …

Dec 2, 2021 HATFIELD, Pa.--(BUSINESS WIRE)--Code Biotherapeutics, Inc., a biotechnology company pioneering targeted non-viral delivery of genetic medicines, announces the …See details»

Code Biotherapeutics Raises Upsized and Oversubscribed $75 …

Jun 7, 2022 For more information, visit www.codebiotx.com. About Northpond Ventures. Northpond Ventures is a multi-billion-dollar science-driven venture capital firm based in …See details»

About Us | Code Biotherapeutics | United States - Code Bio Live Site

Code Bio is led by seasoned leaders with expertise in business, biotechnology and nanotechnology, and is building an internal pipeline focused on select rare disease programs …See details»

Code Biotherapeutics Names Alex S. Tracy, PhD, as Chief Technical ...

Nov 14, 2022 For more information, visit www.codebiotx.com. Contacts. Code Bio Media Contact: Mike Beyer Sam Brown Inc. Healthcare Communications 312-961-2502 …See details»

News: Latest News - Code Bio Live Site

Feb 22, 2022 The Company is advancing an internal pipeline focused on select disease programs while also progressing collaborative partnerships taking forward additional programs …See details»

Code Biotherapeutics Names David Anderson, PhD, as Chief …

Sep 28, 2022 For more information, visit www.codebiotx.com. Contacts Code Bio Media: Mike Beyer Sam Brown Inc. Healthcare Communications 312-961-2502 [email protected]See details»

Code Biotherapeutics Launches with $10 Million in Seed Financing …

Apr 20, 2021 HATFIELD, Pa.--(BUSINESS WIRE)--Code Biotherapeutics, Inc., a next-generation gene therapy company pioneering the development of targeted non-viral gene …See details»

Code Biotherapeutics (@CodeBioTx) / Twitter

Mar 2, 2022 Code Bio is developing transformational, non-viral, genetic medicines to treat and potentially cure serious and life-threatening diseases.See details»

Pipeline | Code Biotherapeutics | United States - Code Bio Live Site

Duchenne Muscular Dystrophy Program . Code Bio’s first gene therapy discovery program is designed to treat Duchenne Muscular Dystrophy (DMD), a debilitating genetic disorder …See details»

Join Us | Code Biotherapeutics | United States - Code Bio Live Site

Code Bio is are always looking for passionate people who are driven by science and innovation to advance the wellbeing of others. If you are interested in working for a company that values …See details»

Code Biotherapeutics Announces Collaboration with Takeda to …

Feb 22, 2022 For more information, visit www.codebiotx.com. Contacts. Code Bio Media Contact: Mike Beyer Sam Brown Inc. Healthcare Communications 312-961-2502 …See details»

News | Code Biotherapeutics | United States - Code Bio Live Site

Dec 2, 2021 Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced a collaboration and option …See details»

linkstock.net © 2022. All rights reserved